Skip to content

Clinical trials

Metabolic Diseases trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Metabolic Diseases Country / region: China Clear all

57 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20113
20133
20141
20152
20161
20173
20181
20203
20214
20224
202311
20247
20256
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed20
Recruiting17
Unknown status9
Not yet recruiting7
Enrolling by invitation2
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company4
Chinese Medical Association3
Ruijin Hospital3
Beijing Friendship Hospital2
First Affiliated Hospital of Chongqing Medical University2
RenJi Hospital2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
Amway (China) R&D Center1
Beijing Sport University1
Children's Hospital of Fudan University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Metabolic Diseases57
Diabetes Mellitus15
Endocrine System Diseases9
Cardiovascular Diseases8
Diabetes Mellitus, Type 28
Glucose Metabolism Disorders8
Obesity7
Hypertension6
Insulin Resistance6
Immune System Diseases4

Trials

Showing 76 to 57 of 57. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.